stars 1 stars 2 stars 3

Genefron is specializing in genomic expression based personal diagnostics in viral and autoimmune diseases. We are using gene expression signatures derived from big data analysis, machine learning algorithm and cell biology knowledge. Genefron has already developed its first 3 personal diagnostic kits (PDK) – all CE marked and with Israeli ministry of health approval: IFR 300 In RA (Rheumatoid Arthritis) patients – a PDK predicting treatment outcome of the ‘Anti TNF’ drug family; - Sell through Meuhedet HMO IFR 100 In MS (Multiple Sclerosis) patients – a PDK predicting treatment outcome of the ‘Interferon β’ drug family IFR 200 – predicting CMV (cytomegalovirus) transmission to fetus in pregnant women - Can be reimburse by Clalit Mashlim

Genefron Ltd. Questions

The Genefron Ltd. annual revenue was $2 million in 2026.

Genefron Ltd. is based in Jerusalem, Jerusalem.

The NAICS codes for Genefron Ltd. are [541, 54171, 541713, 5417, 54].

The SIC codes for Genefron Ltd. are [87, 873].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users